Epidemiology of first-and second-line anti-tuberculosis drug resistance in new pulmonary tuberculosis cases in Addis Ababa metropolitan area, Ethiopia

Abstract

AbstractBackgroundConventional wisdom wrongly holds that the microbiological ofM. tuberculosiscomplex in clinical specimens via culture and phenotypic drug susceptibility testing allows people to be correctly diagnosed and ensures an effective treatment regimen to be selected. This study was aimed to characterize first-and second-line anti-tuberculosis drug resistance profiles among new pulmonary tuberculosis cases in Addis Ababa metropolitan area, Ethiopia.MethodsA prospective cross-sectional study was conducted between October 2019 and June 2021 among bacteriologically confirmed new presumptive pulmonary tuberculosis cases. GeneXpert MTB/RIF Assay was utilized for initial testing and early detection of rifampicin resistance. Mycobacterial culture and drug susceptibility testing were performed against FOUR first-line and ELEVEN second-line anti-TB drugs using BD BACTEC™ MGIT™ 960 automated liquid culture system.ResultsA total of 156M. tuberculosiscomplex isolates were successfully recovered using BD BACTEC™ MGIT™ 960 automated liquid culture system and were subjected to drug susceptibility testing. Males account for 53.8 % (84/156). The median age of the study participants was 30.0 years. Of all the study participants, 58.3 % (91/156) were married, and 76.9% (120/156) were urban residents. Overall, we identified 14.1% (22/156) resistance to at least one anti-TB drug and 85.9% (134/156) pan-susceptibleM. tuberculosisstrains. Further, 7.1% (11/156) of isolates were monoresistant, 5.8% (9/156) of isolates were MDR-TB strains, and 3.8% (6/156) of isolates were resistant to all first-line anti-TB drug regimens. Interestingly, all isolates were susceptible to all recently recommended second-line anti-TB drugs, and none of these isolates were found to be pre-XDR or XDR-TB. The rate of RR-TB detected was 10.9% (17/156) and 5.8% (9/156) using GeneXpert MTB/RIF Assay and BD BACTEC™ MGIT™ 960 SIRE liquid culture system, respectively. The sensitivity, specificity, PPV, NPV, accuracy, and Kappa value were 100%, 94.6%, 52.9%, 100%, 94.9%, and 0.667, respectively.ConclusionThe rate of MDR-TB in new pulmonary TB cases remained high at fivefold the national and nearly twofold the global estimated rate. The rate of monoresistance against anti-TB drugs was also high. The absence of resistance against recommended second-line anti-TB drugs was quite encouraging. However, the high rate of resistance against Ethionamide would mean that its inclusion in the regimens may not have therapeutic benefit in this geographic area. Furthermore, the low specificity of GeneXpert MTB/RIF Assay might introduce a significant rate of (47.1%; 8/17) false rifampicin resistance leading the patient to erroneous MDR-TB category and placing on an unnecessary second-line anti-TB-treatment regimen. Enhanced efforts are required to progressively validate and harmonize rapid molecular diagnostics against reference methods to address the diagnosis challenges and improve patient outcomes.